SYN
Income statement / Annual
Last year (2022), Synthetic Biologics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, Synthetic Biologics, Inc.'s net income was -$19.69 M.
See Synthetic Biologics, Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Research and Development Expenses |
$11.72 M
|
$7.80 M
|
$5.13 M
|
$11.08 M
|
$11.84 M
|
$18.78 M
|
$29.11 M
|
$32.91 M
|
$14.49 M
|
$6.51 M
|
General & Administrative Expenses |
$9.86 M
|
$6.47 M
|
$5.03 M
|
$4.58 M
|
$5.73 M
|
$7.47 M
|
$10.14 M
|
$8.07 M
|
$6.01 M
|
$5.83 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$9.86 M
|
$6.47 M
|
$5.03 M
|
$4.58 M
|
$5.73 M
|
$7.47 M
|
$10.14 M
|
$8.07 M
|
$6.01 M
|
$5.83 M
|
Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Operating Expenses |
$21.58 M
|
$14.27 M
|
$10.16 M
|
$15.66 M
|
$17.57 M
|
$26.25 M
|
$39.25 M
|
$40.98 M
|
$20.50 M
|
$12.34 M
|
Cost And Expenses |
$21.58 M
|
$14.27 M
|
$10.16 M
|
$15.66 M
|
$17.57 M
|
$26.25 M
|
$39.25 M
|
$40.98 M
|
$20.50 M
|
$12.34 M
|
Interest Income |
$512,000.00
|
$6,000.00
|
$44,000.00
|
$283,000.00
|
$67,000.00
|
$21,000.00
|
$37,000.00
|
$6,000.00
|
$3,000.00
|
$33,000.00
|
Interest Expense |
-$471,000.00
|
$6,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Depreciation & Amortization |
$85,000.00
|
$87,000.00
|
$201,000.00
|
$240,000.00
|
$272,000.00
|
$245,000.00
|
$157,000.00
|
$72,000.00
|
$20,000.00
|
$43,000.00
|
EBITDA |
-$21.58 M |
-$14.17 M |
-$9.84 M |
-$15.06 M |
-$13.10 M |
-$14.93 M |
-$27.10 M |
-$43.67 M |
-$19.76 M |
-$12.27 M |
EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Total Other Income/Expenses Net |
$471,000.00
|
$6,000.00
|
$44,000.00
|
$283,000.00
|
$4.15 M
|
$10.76 M
|
$11.45 M
|
-$3.81 M
|
$718,000.00
|
$21,000.00
|
Income Before Tax |
-$21.11 M
|
-$14.27 M
|
-$10.12 M
|
-$15.38 M
|
-$13.42 M
|
-$15.49 M
|
-$27.80 M
|
-$44.79 M
|
-$19.78 M
|
-$12.32 M
|
Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Income Tax Expense |
-$1.43 M
|
$6,000.00
|
$44,000.00
|
$283,000.00
|
$4.15 M
|
$10.76 M
|
$11.45 M
|
-$3.81 M
|
$718,000.00
|
$21,000.00
|
Net Income |
-$19.69 M
|
-$14.27 M
|
-$10.04 M
|
-$15.30 M
|
-$13.37 M
|
-$15.17 M
|
-$27.26 M
|
-$43.74 M
|
-$19.78 M
|
-$12.32 M
|
Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
EPS |
-1.28 |
-1.17 |
-5.28 |
-9.31 |
-21.45 |
-42.7 |
-101.17 |
-189.68 |
-111.78 |
-94.4 |
EPS Diluted |
-1.28 |
-1.17 |
-5.28 |
-9.31 |
-21.45 |
-42.7 |
-101.17 |
-189.68 |
-111.78 |
-94.4 |
Weighted Average Shares Out |
$15.33 M
|
$12.19 M
|
$1.90 M
|
$1.64 M
|
$623,244.00
|
$355,326.00
|
$269,397.00
|
$230,584.00
|
$176,984.00
|
$130,478.00
|
Weighted Average Shares Out Diluted |
$15.33 M
|
$12.19 M
|
$1.90 M
|
$1.64 M
|
$623,244.00
|
$355,326.00
|
$269,397.00
|
$230,584.00
|
$176,984.00
|
$130,478.00
|
Link |
|
|
|
|
|
|
|
|
|
|